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A B S T R A C T
Background: In myocardial ischemia–reperfusion injuries, the involvement of the Na+/H+ exchanger
(NHE) is considered to be one of the pathogenic mechanisms following reperfusion. TY-51924 is a novel
hydrophilic NHE inhibitor with a lower risk of central neurotoxicity than previous NHE inhibitors. This
open-label, dose-escalating study was undertaken to investigate the safety, efﬁcacy, and pharmacoki-
netics of TY-51924 in patients with ST-elevation myocardial infarction (STEMI).
Methods: Consent was obtained from a total of 30 patients with ﬁrst anterior STEMI. After 12 patients
were determined to be ineligible, the remaining 18 patients, each of whom was undergoing primary
percutaneous coronary intervention (pPCI), received TY-51924 intravenously up to 10, 20, or 30 mg/kg
as the low-, medium-, or high-dose groups, respectively (n = 6 in each group). The primary endpoints
were safety (up to 7 days) and plasma drug concentration. The myocardial salvage index (MSI) was
measured by 201Tl/123I-beta-methyl-p-iodophenyl pentadecanoic acid single photon emission computed
tomography (SPECT) 3–5 days after pPCI.
Results: No side effects were observed. Plasma drug concentrations increased dose-dependently, and
were subsequently eliminated rapidly. MSIs were 0.118, 0.335, and 0.192 in the low-, medium-, and
high-dose groups, respectively. In additional analysis, the combined MSIs in the medium- and high-dose
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T. Takayama et al. / Journal of Cardiology 67 (2016) 162–169 163groups were signiﬁcantly higher than those in the low-dose group, in patients with a longer time from symptom
onset to reperfusion (p = 0.0247).
Conclusions: No side effects were observed even at the highest dose with this novel hydrophilic NHE inhibitor.
Therefore, TY-51924 is thought to be safe in patients with STEMI, even at the highest dose. Potential
cardioprotective effects of intravenous TY-51924 might be expected based on the results obtained for the MSIs
using SPECT at 20–30 mg/kg. However, further large-scale, double-blind, placebo-controlled clinical studies are
required to conﬁrm the efﬁcacy and safety implied in the current study.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Early reperfusion by percutaneous coronary intervention (PCI)
is performed for the treatment of ST-segment elevation myocardial
infarction (STEMI) and contributes to reduced infarct size,
improved left ventricular function, and improved survival rates.
However, the Framingham Heart study reported that for PCI, a
decrease in mortality rate after acute myocardial infarction (AMI)
was associated with an increased incidence of heart failure
[1]. Therefore, the development of an adjunctive therapy that
can enhance the therapeutic potential of PCI is required [2]. The
phenomenon of myocardial reperfusion injury, including arrhyth-
mia, myocardial stunning, no-reﬂow, and myocardial infarct
expansion, has been reported [3–5]. Furthermore, it has been
reported that lethal reperfusion injury may account for up to 50% of
the ﬁnal size of a myocardial infarct [6]. Thus, further reductions in
infarct size by the inhibition of myocardial ischemia–reperfusion
injuries are expected [7,8].
The involvement of the Na+/H+ exchanger (NHE) has been
identiﬁed as one of the pathogenic mechanisms of myocardial
ischemia–reperfusion injury [9]. NHE is active at the early phase of
ischemia and reperfusion. Increases in intracellular Na+ via NHE
are excreted through a reverse-mode Na+/Ca2+ exchanger [10]. Dur-
ing this process, an excessive intracellular inﬂux of Ca2+ causes an
intracellular Ca2+ overload, resulting in myocardial cellular injury.
In fact, some studies on NHE inhibitors have indicated the
reduction of infarction size as clinical effects. However, central
nervous system (CNS) side effects have been reported for the
conventional NHE inhibitors, eniporide and cariporide [11,12].
TY-51924 is a novel NHE inhibitor with a water-soluble
functional group, which was intended to separate effective doses
from seriously CNS toxic doses. When TY-51924 was intravenously
administered to rats, no serious histopathological changes were
observed in the CNS. Furthermore, in dog MI models, TY-51924
administered prior to reperfusion signiﬁcantly reduced infarct size
by maintaining plasma drug concentrations in excess of 16.8 mg/mL
at reperfusion, with more remarkable effects observed at 38.8 mg/
mL [13]. In a phase I study, 88 healthy men received an intravenous
infusion of TY-51924 at 0.1–40 mg/kg. No serious adverse events
(SAEs) were observed. Although transient hypesthesia and pain,
which were assumed to be caused by peripheral neuropathy, were
observed at doses above 16 mg/kg, these did not require treatment.
In addition, as a cause of the cerebrovascular events in EXPEDITION,
it was suggested that prolonged NHE inhibition and abrupt drug
withdrawal could lead to platelet hyperactivity as a rebound
phenomenon [12]. The effects of TY-51924 on platelet aggregation
were not observed in the phase I study (data not published), and the
duration of drug administration in this study was much shorter than
that in EXPEDITION. These results indicated that TY-51924 may be
safe and well-tolerated at doses up to 40 mg/kg.
In this paper, we report the results of a phase IIa ﬁrst-in-patient
pilot study designed to evaluate the safety, efﬁcacy, and
pharmacokinetics of TY-51924 after single-bolus and continuous
intravenous injection in patients with ﬁrst anterior STEMI
undergoing primary PCI (pPCI).Methods
Study design
This study was a multicenter open-label study in Japan with a
group titration design. Patients were assigned to three groups:
low-, medium-, and high-dose. Prior to patient enrollment, this
study was approved by each institutional review board. This study
was conducted in accordance with the ethical principles of the
Declaration of Helsinki and Good Clinical Practice. Notiﬁcation of
the clinical trial plan was submitted to the Pharmaceuticals and
Medical Devices Agency, Japan in September 2010. An overview of
the plan is registered in the JapicCTI database (JapicCTI-111386;
http://www.japic.or.jp/).
Study population
The study population consisted of Japanese patients with new-
onset STEMI, who were undergoing pPCI after admission within 6 h
of symptom onset and had a thrombolysis in myocardial infarction
(TIMI) ﬂow grade of 0/1 in the left anterior descending artery (LAD)
on diagnostic coronary angiography (CAG). Details of the inclusion
and exclusion criteria are shown in supplementary material. All
patients provided written informed consent for participation in the
study.
Protocol
The study protocol is shown in Table 1. After conﬁrmation of
eligibility, a bolus intravenous administration of 2, 4, or 6 mg/kg
TY-51924 (low-, medium-, and high-dose groups, respectively)
was performed before guidewire crossing. Immediately after bolus
administration, continuous intravenous administration was initi-
ated at a rate of 8, 16, and 24 mg kg1 h1 (low-, medium-, and
high-dose groups, respectively). Administration was completed
10 min after conﬁrmation of TIMI ﬂow grade 2/3 on CAG
immediately after PCI completion. Even if TIMI ﬂow grade 2/3 was
not conﬁrmed within 1 h, continuous administration was com-
pleted within 1 h from the start of administration. The maximum
doses of TY-51924 in each group were 10, 20, and 30 mg/kg (low-,
medium-, and high-dose groups, respectively). Administration was
initiated from the low-dose group. Patients in the next group were
examined after administration to six patients in the prior group
was completed and after safety had been conﬁrmed based on
reports of adverse events (AEs) obtained <48 h after the start of
administration to the sixth patient and safety information already
obtained at 48 h after the start of administration to the ﬁrst ﬁve
patients.
Except for unavoidable cases, intravenous administration
of carperitide and nicorandil was prohibited during the
study period. Other concomitant drugs or therapies were not
limited, and PCI was performed in accordance with the
methods used at each site. CAG was performed, and data with
patient information concealed were sent to the CAG core
laboratory.
Table 1
Schedule of assessments.
Day 1 D 2 D 3 D 4 D 5 D 7 D
Study procedures Before PCI During PCI Completion of
administration
3 h 6 h 9 h 12 h 24 h
Informed consent/patient characteristics *
Consultation * * * * *
Chest pain **1 **1
12-Lead ECG **2 **2 **3 * *
ECG monitoring
Body temperature and respiratory rate * * *
Blood pressure and heart rate * **4 * *
Laboratory test * * * *
Cardiac enzyme * * * * * * * * *
CAG **5
Study drug administration
201Tl/123I-BMIPP dual-isotope SPECT*6
Plasma drug concentration * * * *
Adverse event follow-up
PCI, percutaneous coronary intervention; ECG, electrocardiography; CAG, coronary angiography; BMIPP, beta-methyl-p-iodophenylpentadecanoic acid; SPECT, single
photon emission computed tomography.
*1: Before PCI = measurement at the time of the start of PCI; during PCI = measurement at the time of ﬁrst achievement of TIMI 2/3.
*2: Before PCI = measurement at the time of entering a catheterization laboratory to before the start of administration; during PCI = measurement at the time of ﬁrst
achievement of TIMI 2/3 during PCI and at the time of completion of PCI (or leaving a catheterization laboratory).
*3: Measurement at the time of entering the CCU.
*4: Recording every 10 min from the start of administration to the completion of administration.
*5: Measurement before and after PCI.
*6: Individual imaging at sites where dual-isotope SPECT is difﬁcult to perform.
: Perform continuously throughout the period. : Perform once during the period.
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Plasma drug concentration evaluation
Plasma drug concentrations of TY-51924 were measured using
blood collected immediately before the completion of administra-
tion, and at 3, 6, and 24 h after the start of administration. Plasma
drug concentrations were measured centrally at a single general
laboratory (BML Co., Kawagoe, Saitama, Japan).
Safety evaluation
For safety evaluation, AEs and side effects were monitored from
administration to the seventh day. All AEs were coded into a
common dictionary (MedDRA). Standard 12-lead electrocardiog-
raphy (ECG), monitoring ECG, body temperature, respiratory rate,
blood pressure, heart rate, and laboratory parameters were
measured according to the schedule (Table 2).
Secondary endpoints
Single-photon emission computed tomography (SPECT) evaluation
Evaluation using 201Tl/123I-beta-methyl-p-iodophenyl penta-
decanoic acid (BMIPP)-gated dual-isotope SPECT was performed
3–5 days after PCI. A total of 111 MBq of Cardiodine1 Injectable
123I-BMIPP (Nihon Medi-Physics Co., Ltd.) and 111 MBq of
Thallium (201Tl) Chloride Injectable NMP (Nihon Medi-Physics
Co., Ltd.) were applied. Image processing of the raw projection data
was performed at the SPECT core laboratory. An earlier report [14]
had calculated risk and infarct sizes by contrasting data with that
from normal databases [15,16] for 123I-BMIPP and 201Tl using
Quantitative Perfusion SPECT software (Cedars-Sinai Medical
Center, Los Angeles, CA, USA). In calculation of the left ventricular
ejection fraction (LVEF), Quantitative Gated SPECT software
(Cedars-Sinai Medical Center) was used.
Electrocardiography evaluation
ECG data were sent to the ECG core laboratory and evaluated.
For the analysis of the degree of myocardial damage, QRS scores
[17] and ST resolution [18–20] were evaluated. In addition, as oneof the indices of reperfusion injury, ST-segment re-elevation at the
time of ﬁrst achievement of TIMI 2/3 during PCI was evaluated
[21].
Other evaluations
The following CAG data were evaluated: American Heart
Association (AHA) classiﬁcation of coronary lesions, TIMI ﬂow
grade, Rentrop grade in collateral ﬂow, corrected TIMI frame count
(cTFC), and myocardial blush grade. As cardiac enzymes, creatine
kinase (CK), CK-MB, and troponin T were measured. Blood samples
were measured centrally, and peak values and areas under the
curve were calculated. The degree of chest pain before PCI and at
the time of ﬁrst achievement of TIMI 2/3 was evaluated using a
numerical rating scale [22]. In addition, any cases of ventricular
arrhythmia (NSVT/SVT and Vf/VF) which occurred after study drug
administration were recorded.
Determination of endpoints
Primary endpoints included pharmacokinetics and the inci-
dence of AEs and side effects up to day 7.
Secondary endpoints included radionuclide imaging (myocar-
dial area at risk (AAR), infarct size, myocardial salvage index (MSI),
and left ventricular function), cardiac enzymes, 12-lead ECG (QRS
scores, ST-segment re-elevation and ST resolution), degree of chest
pain, and occurrence of ventricular arrhythmia. MSI was calculated
from the following formula: MSI = (AAR  infarct size)/AAR [23].
Statistical analysis
The sample size design was not statistically evaluated. The
minimum sample size necessary for exploratory evaluation of the
safety, efﬁcacy, and pharmacokinetics was set to 6 in each group.
The two-sided signiﬁcance level was set at 0.05. When interval
estimations were performed, the conﬁdence coefﬁcient was 95%.
Continuous variables were summarized as mean and standard
deviation (SD), and inter-group comparisons were conducted using
one-way analysis of variance or Student’s t-test. The Wilcoxon rank
Table 2
Baseline characteristics.
Low-dose group Medium-dose group High-dose group Total p-Value
n 6 6 6 18
Age (years) 59.2  13.9 62.0  17.3 59.7  10.4 60.3  13.3 0.9338
Sex, n (%)
Male 6 (100.0%) 5 (83.3%) 5 (83.3%) 16 (88.9%) 1.0000
Female 0 (0.0%) 1 (16.7%) 1 (16.7%) 2 (11.1%)
Height (cm) 174.0  7.4 171.0  2.9 167.5  11.2 170.8  8.1 0.4088
Weight (kg) 83.2  20.1 68.2  11.3 73.8  16.2 75.1  16.6 0.3022
BMI 27.28  5.20 24.52  2.11 26.13  4.10 26.06  4.01 0.5537
Killip classiﬁcation, n (%)
I 4 (66.7%) 6 (100.0%) 6 (100.0%) 16 (88.9%) 0.2941
II 2 (33.3%) 0 (0.0%) 0 (0.0%) 2 (11.1%)
III 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
History of anfgina pectoris, n (%)
Total 3 (50.0%) 3 (50.0%) 1 (16.7%) 7 (38.9%) 0.5757
>48 h before admission 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Within 48 h before admission 3 (100.0%) 3 (100.0%) 1 (100.0%) 7 (100.0%)
Previous coronary revascularization, n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Complication, n (%)
Total 5 (83.3%) 5 (83.3%) 5 (83.3%) 15 (83.3%) 1.0000
Hypertension 2 (40.0%) 3 (60.0%) 3 (60.0%) 8 (53.3%) 1.0000
Dyslipidemia 4 (80.0%) 3 (60.0%) 3 (60.0%) 10 (66.7%) 1.0000
Diabetes mellitus 3 (60.0%) 1 (20.0%) 1 (20.0%) 5 (33.3%) 0.5273
Smoking, n (%) 3 (50.0%) 1 (16.7%) 3 (50.0%) 7 (38.9%) 0.5757
Time from symptom onset (min)
To admission 66.5  43.5 75.2  30.1 123.8  70.3 88.5  54.3 0.1428
To study drug administration 127.2  67.0 119.5  24.2 184.8  60.8 143.8  59.0 0.1057
To ﬁrst achievement of TIMI 2/3 during PCI 133.7  65.6 128.0  26.2 198.0  64.4 153.2  61.3 0.0815
Time from admission to ﬁrst achievement of
TIMI 2/3 during PCI (min)
67.2  36.9 52.8  17.7 74.2  17.3 64.7  25.8 0.3654
Time from study drug administration to ﬁrst
achievement of TIMI 2/3 during PCI (min)
6.5  3.9 8.5  4.0 13.2  8.9 9.4  6.4 0.1835
Time from initiation to completion of study
drug administration (min)
54.8  7.0 45.2  17.1 51.5  13.2 50.5  13.0 0.4494
Systolic blood pressure before PCI (mmHg) 144.7  19.0 154.8  27.2 143.5  34.1 147.7  26.3 0.7389
Diastolic blood pressure before PCI (mmHg) 90.7  16.0 94.8  19.8 90.5  17.2 92.0  16.8 0.8926
Heart rate before PCI (beats per min) 82.0  10.6 71.2  12.9 69.7  15.5 74.3  13.6 0.2387
Q-wave in 12-lead ECG
Criteria 1*1 3 (50.0%) 5 (83.3%) 4 (66.7%) 12 (66.7%) 0.5273
Criteria 2*2 4 (66.7%) 5 (83.3%) 4 (66.7%) 13 (72.2%) 1.0000
The number of leads with ST elevation
Criteria 1*3 6.2  1.7 4.5  1.2 6.0  1.6 5.5  1.6 0.1541
Criteria 2*4 6.5  1.9 5.3  1.5 6.4  1.1 6.1  1.6 0.3894
CAG
AHA classiﬁcation, n (%)
Segment 6 4 (66.7%) 2 (33.3%) 3 (50.0%) 9 (50.0%) 0.8354
Segment 7 2 (33.3%) 4 (66.7%) 3 (50.0%) 9 (50.0%)
TIMI ﬂow grade before PCI, n (%)
Grade 0 5 (83.3%) 6 (100.0%) 5 (83.3%) 16 (88.9%) 1.0000
Grade 1 1 (16.7%) 0 (0.0%) 1 (16.7%) 2 (11.1%)
Rentrop grade, n (%)
Grade 0 2 (33.3%) 1 (16.7%) 3 (50.0%) 6 (33.3%) 0.5962
Grade 1 3 (50.0%) 4 (66.7%) 2 (33.3%) 9 (50.0%)
Grade 2 1 (16.7%) 0 (0.0%) 1 (16.7%) 2 (11.1%)
Grade 3 0 (0.0%) 1 (16.7%) 0 (0.0%) 1 (5.6%)
PCI therapy, n (%)
Stent 6 (100.0%) 5 (88.3%) 6 (100.0%) 17 (94.4%) 1.0000
Thrombus suction therapy 6 (100.0%) 5 (88.3%) 4 (66.7%) 15 (83.3%) 0.7352
Peripheral protection device 0 (0.0%) 1 (16.7%) 1 (16.7%) 2 (11.1%) 1.0000
TIMI ﬂow grade at the time of
PCI completion*5, n (%)
Grade 2 1 (16.7%) 0 (0.0%) 1 (16.7%) 2 (11.1%) 1.0000
Grade 3 5 (83.3%) 5 (83.3%) 5 (83.3%) 15 (83.3%)
cTFC*5 29.88  13.45 18.62  7.68 27.95  12.86 25.89  12.13 0.2858
Myocardial blush grade*5, n (%)
Grade 0 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.3089
Grade 1 3 (50.0%) 0 (0.0%) 2 (33.3%) 5 (27.8%)
Grade 2 2 (33.3%) 4 (66.7%) 4 (66.7%) 10 (55.6%)
Grade 3 1 (16.7%) 1 (16.7%) 0 (0.0%) 2 (11.1%)
Values expressed as mean  standard deviations. BMI, body mass index; TIMI, thrombolysis in myocardial infarction; PCI, percutaneous coronary intervention; CAG, coronary
angiography; AHA, American Heart Association; ECG, electrocardiography; cTFC, corrected TIMI frame count.
*1: The presence of Q-waves in two adjacent leads among V1–V3.
*2: The presence of Q-waves (any Q-waves in lead V2) or Q-wave equivalents (R-waves with 0.1 mV or <10 ms in lead V2).
*3: The number of leads with ST-segment elevation of 0.1 mV at 20 ms from the terminal component of the QRS complex.
*4: The number of leads with ST-segment elevation of 0.1 mV at 80 ms from the J-point.
*5: No data due to the occurrence of a serious adverse event.
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Table 3
Plasma drug concentration.
Low-dose
group
Medium-dose
group
High-dose
group
p-Value
n 6 5 6
Immediately before
completion of
administration
22.7  4.7 45.58  10.1 84.6  8.2 <0.0001
3 h after the start of
administration
1.4  0.6 2.8  1.9 5.5  2.8 0.0101
6 h after the start of
administration
0.2  0.1 0.4  0.4 0.7  0.4 0.0681
24 h after the start of
administration
0.0  0.0 0.0  0.0 0.0  0.0 –
Values expressed as mean  standard deviations. Units are in mg/mL.
Summary statistics were calculated with data below the limit of quantiﬁcation
(N.D.) shown as zero.
Table 4
Adverse events during the study period.
Low-dose
group
Medium-dose
group
High-dose
group
n 6 6 6
Myocardial rupture 0 (0%) 1 (16.7%) 0 (0%)
Ventricular tachycardia 1 (16.7%) 2 (33.3%) 3 (50.0%)
Nausea 0 (0%) 0 (0%) 2 (33.3%)
Thrombosis in device 0 (0%) 0 (0%) 1 (16.7%)
Body temperature increased 0 (0%) 1 (16.7%) 0 (0%)
Musculoskeletal pain 0 (0%) 0 (0%) 1 (16.7%)
Insomnia 0 (0%) 1 (16.7%) 0 (0%)
Cough 0 (0%) 0 (0%) 2 (33.3%)
Epistaxis 0 (0%) 1 (16.7%) 0 (0%)
Orthostatic hypotension 0 (0%) 0 (0%) 1 (16.7%)
Total 1 (16.7%) 3 (50.0%) 5 (83.3%)
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tions. The relationships between the MSI and the time from onset
to reperfusion were analyzed using the Spearman rank-correlation
method. Categorical variables were summarized as number of
subjects and percentage, and inter-group comparisons were
conducted using Fisher’s exact test or Kruskal–Wallis test. For
AEs and side effects up to day 7, the incidence was calculated by
dose group. For plasma drug concentrations of TY-51924,
mean  SD, maximum, minimum, and median values were evaluated
for each dose group. The statistical analysis was performed using SAS
software, versions 9.1.3 and 9.2 (SAS Institute Japan Ltd., Tokyo,
Japan).
Results
Study population and characteristics
From December 2010 to June 2011, a total of 30 patients gave
consent. After 12 patients were considered ineligible before theTable 5
Single-photon emission computed tomography results.
n Low-dose group n Medium-dose group n 
Mean  SD 95% CI Mean  SD 95% CI M
AAR (%) 6 46.0  9.0 36.6–55.4 4 38.0  5.8 28.8–47.2 6 4
IS (%) 6 41.3  14.2 26.4–56.2 4 25.3  3.8 19.2–31.3 6 3
MSI 6 0.118  0.167 0.057–0.294 4 0.335  0.010 0.319–0.351 6 0.1
LVESV (mL) 6 87.5  28.7 57.4–117.6 4 59.3  32.0 8.3–110.2 5 6
LVEDV (mL) 6 128.3  32.6 94.1–162.6 4 107.8  42.0 40.9–174.6 5 10
LVEF (%) 6 32.5  6.8 25.3–39.7 4 46.8  8.1 33.9–59.6 5 4
AAR, area at risk; CI, conﬁdence interval; IS, infarct size; MSI, myocardial salvage index
volume; LVEF, left ventricular ejection fraction; SD, standard deviations.
*1: vs low-dose group.study drug administration, a total of 18 patients (n = 6, each group)
received the study drug and were included in the safety analysis
set according to the protocol. One patient in the medium-dose
group discontinued due to SAE; this patient was excluded from the
pharmacokinetic analysis set due to the absence of data on the
plasma drug concentrations. For efﬁcacy analysis, select data from
two patients were excluded; in one patient who discontinued the
study, data after discontinuation were excluded, and in one patient
who received prohibited concomitant drugs in the medium-dose
group, data on efﬁcacy after administration of the prohibited drug
were excluded.
Patient characteristics are shown in Table 2. The population
consisted of 16 men (88.9%) with a mean age of 60.3  13.3 years,
weight of 75.1  16.6 kg, and BMI of 26.06  4.01. The time from
symptom onset to the ﬁrst achievement of TIMI 2/3 (reperfusion
time) was 133.7  65.6, 128.0  26.2, and 198.0  64.4 min in the
low-, medium-, and high-dose groups, respectively. The mean
reperfusion time was 3 h only in the high-dose group. In the CAG
ﬁndings, total occlusion of distal LAD was observed most frequently
in the medium-dose group.
Primary endpoints
Plasma drug concentration
Changes in plasma drug concentrations are shown in
Table 3. The plasma drug concentrations immediately before the
completion of study drug administration were 22.7  4.7 mg/mL,
45.6  10.1 mg/mL, and 84.6  8.2 mg/mL in the low-, medium-, and
high-dose groups, respectively, showing signiﬁcant dose-dependent
increases (p < 0.0001). Elimination was rapid regardless of dose, and
the concentrations were below the limit of detection by 24 h after the
start of administration.
Safety endpoint
All AEs are presented in Table 4. AEs were reported in one
(16.7%), three (50.0%), and ﬁve patients (83.3%) in the low-,
medium, and high-dose groups, respectively. There is no signiﬁ-
cant difference between the low- and high-dose groups in terms of
the prevalence of AEs. Most frequent AEs were ventricular
tachycardia, all these events were NSVT. SAEs were reported in
one patient in the medium-dose group (myocardial rupture) and
one patient in the high-dose group (thrombus in medical device
(stent thrombosis)). All events were assessed as unrelated to the
study drug, and no side effects were observed. Changes in blood
pressure and heart rate during administration were observed
during PCI; no variation was caused by the study drug.
Secondary endpoints
SPECT
SPECT results are shown in Table 5. In the low-, medium-, and
high-dose groups, the AAR was 46.0  9.0%, 38.0  5.8%, andHigh-dose group p-Value n Medium–high dose group p-Value*1
ean  SD 95% CI Mean  SD 95% CI
3.2  8.8 33.9–52.4 0.3552 10 41.1  7.8 35.5–46.7 0.2703
5.2  12.5 22.1–48.3 0.1495 10 31.2  10.8 23.4–39.0 0.1284
92  0.184 0.002–0.385 0.1320 10 0.249  0.156 0.137–0.361 0.1365
3.2  23.7 33.8–92.6 0.2467 9 61.4  25.9 41.6–81.3 0.0900
8.4  21.9 81.2–135.6 0.5135 9 108.1  30.0 85.0–131.2 0.2385
3.4  11.1 29.6–57.2 0.0536 9 44.9  9.4 37.6–52.1 0.0162
; LVESV, left ventricular end systolic volume; LVEDV, left ventricular end diastolic
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Fig. 1. Correlation between the reperfusion time and the MSI. The reperfusion time was associated with signiﬁcantly reduced MSI in the low-dose group (p = 0.0416;
signiﬁcance testing of the Spearman rank correlation coefﬁcient). On the other hand, the time-associated reduction of the MSI disappeared in the medium-high dose group.
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Fig. 2. Comparison of MSIs between TY-51924 low-dose and medium-high dose
groups. The medium-high dose group was associated with a signiﬁcantly greater
MSI, compared with the low-dose group in patients with reperfusion time 90 min
(p = 0.0247). MSI, myocardial salvage index.
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25.3  3.8%, 35.2  12.5%, respectively, and the MSI was
0.118  0.167, 0.335  0.010, and 0.192  0.184, respectively, show-
ing no signiﬁcant differences between the three groups.
We further evaluated the efﬁcacy of TY-51924 by comparing
the results from the low-dose group with the combined results
from the medium- and high-dose groups (medium-high dose
group). The mean MSI was 0.118, and 0.249 respectively
(p = 0.1365), demonstrating a trend toward better myocardial
salvation in the medium-high dose group (Table 5). The correlation
between the reperfusion time and the MSI is shown in Fig. 1. The
value of the Spearman correlation coefﬁcient between the MSI and
the time from onset to reperfusion was 0.8286 (p = 0.0416) in the
low-dose group, and 0.2523 (p = 0.4818) in the medium-high
dose group. Therefore, we made the further analysis excluding
patients with very early reperfusion time (<90 min). When the MSI
values within the subgroup of patients with reperfusion time
90 min were compared for the low- and medium-high dose
groups, the MSI was signiﬁcantly higher in the medium-high dose
group (p = 0.0247, Fig. 2).
Other efﬁcacy endpoints
Results of other efﬁcacy endpoints are shown in
Table 6. Although cardiac enzymes and QRS scores tended to be
lower in the medium-dose group as a whole, no constant
tendencies between groups were observed. ST-segment elevation
resolution tended to be smaller in the medium-dose group. No
differences were observed in ST-segment re-elevation, degree of
chest pain, or occurrence of ventricular arrhythmia.
Discussion
This was the ﬁrst clinical study assessing the safety and
pharmacokinetics of intravenous TY-51924 in patients with STEMI.
The plasma concentration of TY-51924 increased in a dose-
dependent manner with fast elimination, and no serious side
effects were observed. Although SAEs were reported in one patient
each in the medium- and high-dose groups, they were considered
natural courses in the treatment process of AMI and appeared to be
unrelated to TY-51924. Although one patient died after rupture in
the medium-dose group, the patient presented a risk formyocardial rupture, age, and female gender, which is easy to
predict at onset. It has been reported that there was increased
psychiatric confusion associated with cariporide compared with
placebo [12]. Importantly, TY-51924 did not cause any CNS
symptoms typically associated with NHE inhibitors during this
study. TY-51924 was speciﬁcally designed to be hydrophilic to
avoid the CNS adverse effects, and showed very low distribution to
central nervous tissue. Therefore, we consider that neurotoxicity
risk of NHE inhibitor might be reduced in TY-51924. Furthermore,
no AEs caused by peripheral neuropathy, such as the hypesthesia
reported in the phase I study were observed. Thus, TY-51924 was
safely administered to the patients in this study.
In the pharmacokinetics evaluation, concentrations of
16.8 mg/mL were certainly maintained during administration,
at least in the medium-dose group, while concentrations of
38.8 mg/mL were maintained in the high-dose group. From these
results, it is expected that the targeted plasma drug concentrations
(effective blood concentrations in dog MI model [13]) of TY-51924
can be obtained, at least in the medium-dose group.
Table 6
Other efﬁcacy endpoints.
n Low-dose group n Medium-dose group n High-dose group p-Value
Mean  SD 95% CI Mean  SD 95% CI Mean  SD 95% CI
CK
AUC (U h1 L1) 6 131,805  33,319 96,838–166,771 4 86,677  35,793 29,722–14,3632 6 119,425  34,946 82,752–156,098 0.1620
Peak (U/L) 6 4651  1710 2856–6445 4 3645  2411 191–7481 6 4940  1707 3149–6731 0.5694
CK-MB
AUC (ng h1mL1) 6 13,510  7576 5560–21,461 4 11,465  4544 4235–18,695 6 14,543  2320 12,108–16,977 0.6810
Peak (ng/mL) 6 613.57  270.48 329.72–897.41 4 617.00  349.01 61.65–172.35 6 847.03  307.31 524.53–1169.54 0.3646
Troponin T
AUC (ng h1mL1) 6 379.0  125.4 247.4–510.6 4 341.7  122.5 146.8–536.6 6 504.9  235.5 257.7–752.1 0.3160
Peak (ng/mL) 6 11.0  5.4 5.3–16.6 4 13.8  7.9 1.3–27.0 6 17.4  6.7 10.4–24.4 0.2660
72-h value (ng/mL) 6 3.5  1.1 2.4–4.7 4 3.3  1.1 1.5–5.0 6 4.5  2.4 2.0–7.0 0.4761
QRS score
Before PCI 6 4.8  2.8 1.9–7.8 5 4.8  0.8 3.8–5.8 5 6.4  3.1 2.5–10.3 0.1805
At the time of
completion of PCI
6 9.7  4.5 5.0–14.3 5 7.0  3.2 3.0–11.0 5 9.6  4.2 4.4–14.8 0.4931
At the time of
entering CCU
6 9.2  3.7 5.3–13.1 5 7.6  2.5 4.5–10.7 5 10.2  4.8 4.3–16.1 0.4378
Day 2 6 11.2  4.1 6.9–15.4 4 7.5  1.7 4.7–10.3 5 9.6  3.6 5.2–14.0 0.2653
Day 7 6 9.8  2.8 6.9–12.8 4 6.0  0.8 4.7–7.3 5 10.6  5.3 4.0–17.2 0.1092
n Low-dose group n Medium-dose group n High-dose group p-Value
Number of patients (%) Number of patients (%) Number of patients (%)
ST resolution
Criteria 1 [16]*1
At the time of
completion of PCI
6 2 (33.3) 4 2 (50.0) 5 3 (60.0) 0.8135
At the time of
entering CCU
6 4 (66.7) 5 1 (20.0) 5 4 (80.0) 0.2045
Criteria 2 [17]
At the time of
completion of PCI
6 2 (33.3) 4 0 (0.0) 5 2 (40.0) 0.4725
At the time of
entering CCU
6 3 (50.0) 5 1 (20.0) 5 3 (60.0) 0.5629
Criteria 3 [18]
At the time of
completion of PCI
6 2 (33.3) 4 0 (0.0) 5 1 (20.0) 0.7362
At the time of
entering CCU
6 2 (33.3) 5 1 (20.0) 5 2 (40.0) 1.0000
ST re-elevation
Criteria 1 6 2 (33.3) 5 1 (20.0) 5 3 (60.0) 0.5629
Criteria 2 6 2 (33.3) 5 1 (20.0) 5 3 (60.0) 0.5629
Increased chest pain 6 0 (0.0) 6 0 (0.0) 6 1 (16.7) 1.0000
Ventricular arrhythmia 6 0 (0.0) 6 0 (0.0) 6 1 (16.7) 1.0000
CK, creatine kinase; AUC, area under the curve; CCU, coronary care unit; CI, conﬁdence interval; PCI, percutaneous coronary intervention; SD, standard deviations.
*1: The number of patients with partial resolution.
T. Takayama et al. / Journal of Cardiology 67 (2016) 162–169168In the efﬁcacy evaluation, because ischemia size at the time of
AMI onset greatly differs between patients, which affects infarct
size, an evaluation of MSI based on AAR in each patient is
important for the assessment of a drug’s treatment effects.
Therefore, in this study, we used MSI assessed by 201Tl/123I-BMIPP
dual-isotope SPECT. 123I-BMIPP, the uptake of which into cells is
decreased due to a fatty-acid metabolism disorder caused by
ischemia, represents AAR. In addition, the deﬁcit of 201Tl represents
infarct size. Cardiac magnetic resonance imaging has emerged as a
potential alternative approach. However, there are several con-
cerns including the technical limitations [24]. Therefore, the choice
of these SPECT methods was appropriate in this study. In fact,
Fukuzawa et al. reported the effectiveness of nicorandil for AMI
assessed by 201Tl/123I-BMIPP dual-isotope SPECT [25].
In this study, no clear dose-response relationship was observed
because the statistical power might not be sufﬁcient for detecting
such differences. The blood concentration level in the medium-
dose group met the efﬁcacious level shown in dog MI models. Thus,
we carried out further analysis by comparing the results of the low-
dose group with the combined medium-high dose group.
Ortiz-Pe´rez et al. showed that MSI varied progressively with
increasing symptom-to-balloon time [26]. In this study, although
the reperfusion time was longer in the high-dose group, the MSIshowed a trend toward improvement in the medium-high dose
group (Tables 2 and 5). Scatter plots showed that the time of delay
from symptom onset to reperfusion was associated with signiﬁ-
cantly reduced MSIs in the low-dose group. On the other hand,
MSIs in the medium-high dose group were likely to remain high,
even in patients reperfused a long time after onset (Fig. 1). Thus, we
conducted an additional analysis, the results of which suggest that
the MSIs in the medium-high dose group were signiﬁcantly higher,
even in patients reperfused a longer time after onset (Fig. 2).
Although no signiﬁcant difference was found in the CAG
evaluations, for this deﬁnition of MSI, which was calculated by
incorporating the degree of AAR before reperfusion, the medium-
high dose group tended to show beneﬁts compared with the low-
dose group. In subsequent studies, the use of a medium- or high-
dose may be necessary to prove the efﬁcacy of TY-51924.
Limitations
There are several study limitations. Firstly, in the current study,
TY-51924 was safe during the 1 week after intravenous
administration. Nevertheless, the long-term outcomes were not
analyzed. Secondly, this study included a small number of patients,
and lacked the statistical power to detect differences for various
T. Takayama et al. / Journal of Cardiology 67 (2016) 162–169 169efﬁcacy endpoints; accordingly, clear conclusions regarding the
drug activity of TY-51924 could not be drawn. Finally, a possible
bias in the results cannot be denied, because this study was open
and no placebo was used as a control.
Conclusions
With the use of a novel hydrophilic NHE inhibitor, TY-51924,
side effects were not observed even at the highest dose. Therefore
TY-51924 is thought to be safe in patients with STEMI. The
potential cardioprotective effect of intravenous TY-51924 might be
expected based on the results obtained for the MSIs using SPECT at
20–30 mg/kg. However, further large-scale, double-blind, placebo-
controlled clinical studies are required to conﬁrm the efﬁcacy and
safety implied in the current study.
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